ライフサイエンスコーパス: tissue factor

1 kb upstream from F3, coagulation factor III (tissue factor).

2 lified TG initiated by low concentrations of tissue factor.

3 logic expression of the procoagulant protein tissue factor.

4 hat it must compete with endogenous FVII for tissue factor.

5 on by factor VIIa in the presence of soluble tissue factor.

6 macrophages, but enhanced the expression of tissue factor.

7 ted Thrombogram assay triggered with 1microM tissue factor.

8 ation (up to 1.6-fold) when initiated by low tissue factor.

9 actor XIa, plasma kallikrein, or factor VIIa/tissue factor.

10 ellular adhesion molecule-1, E-selectin, and tissue factor.

11 tive coagulopathy initiated by exposed brain tissue factor.

12 of CpG DNA on the expression and activity of tissue factor, a key initiator of coagulation and tissue

13 (FXa) via a slow-tight binding mechanism and tissue factor-activated FVII (TF-FVIIa) via formation of

14 In addition, microvesicle tissue factor activity and interleukin-8 levels were sig

15 etween plasma interleukin-8 and microvesicle tissue factor activity measured on admission in patients

16 Mice with low tissue factor activity succumb to yersiniosis with a phe

17 g the redox-sensitive probe dihydroethidium, tissue factor activity using an enzymatic Tenase assay,

18 ed on ICU day 1, only increased microvesicle tissue factor activity was significantly associated with

19 Microvesicle tissue factor activity, thrombin-antithrombin complexes,

20 senger RNA and protein levels, as well as in tissue factor activity.

21 ionally increased and express high levels of tissue factor and CD62P in HIV-1 infection.

22 eading to local delivery of monocyte-derived tissue factor and cytokines.

23 -kappaB levels and NF-kappaB-dependent genes tissue factor and IL-6 were increased compared with cont

24 lic artery (26%), with reduced expression of Tissue factor and MMP9.

25 Renal expression of tissue factor and other inflammatory factors increased w

26 L5 but not L1 induced tissue factor and P-selectin expression in human aortic

27 eural administration of MPM cells expressing tissue factor and PAR1 but lacking EPCR and PAR2 (F2RL1)

28 Leukocytes can be induced to express tissue factor and release proinflammatory and procoagula

29 -NGR consists of the extracellular domain of tissue factor and the peptide GNGRAHA, a ligand of the s

30 was dependent on both tumor cell-associated tissue factor and thrombin procoagulant function.

31 chanisms, coagulation factors, in particular tissue factor and thrombin, might also participate in th

32 helial cell was challenged with CpG DNA, and tissue factor and tissue factor pathway inhibitor expres

33 Toll-like receptor 9 shifted the balance of tissue factor and tissue factor pathway inhibitor toward

34 pendently associated with elevated levels of tissue factor and tissue plasminogen activator.

35 coagulant activation with high expression of tissue factor and vWF, and low expression of the ectonuc

36 elial inflammation, white blood cell-derived tissue factor, and ample red blood cell incorporation.

37 PAR-2 ligands, mast cell tryptase, trypsin, tissue factor, and kallikrein (KLK) 5 and KLK14, were as

38 ch as alphaIIbbeta3, alphavbeta3, GPIbalpha, tissue factor, and thrombospondin.

39 ment with inhibitory oligonucleotide or anti-tissue factor antibody or genetic deletion of TLR9 preve

40 This effect was reversed with an anti-tissue factor antibody.

41 xidized LDL and circulating monocyte-derived tissue factor are important instigating factors driving

42 To explore the possibility of using tissue factor as a target for an antibody-drug conjugate

43 Alternatively spliced tissue factor (asTF) is a novel isoform of full-length t

44 The results for tissue factor-bearing microparticles are heterogeneous:

45 dhesion of neutrophils in venules, generated tissue factor-bearing microparticles, shortened plasma-c

46 on or platelet aggregation triggered by high tissue factor, but it increased thrombin generation rate

47 flammatory cells through their expression of tissue factor can directly affect hemostasis and thrombo

48 oter was activated, and forced expression of tissue factor cDNA was achieved in MCF-7 cells, implying

49 rombin potential was markedly reduced at low-tissue factor concentration, and failure to correct with

50 calibrated platelet aggregation model with a tissue-factor/contact pathway coagulation cascade, repre

51 Mechanistically, adipocyte tissue factor cytoplasmic domain-dependent VIIa signalin

52 Platelet-specific APLs optimally supported tissue factor-dependent coagulation in human plasma, vs.

53 emonstrate critical protective roles for the tissue factor-dependent extrinsic coagulation pathway du

54 pressed EPCR and PAR1 with minimal levels of tissue factor did not increase their limited tumorigenic

55 high wall shear stresses, and plaque-derived tissue factor driving thrombin production.

56 pecific 6 (Gas6) regulates the expression of tissue factor during venous thrombosis, and (2) cancer p

57 this study, we investigated the influence of tissue factor, endothelial cell protein C receptor (EPCR

58 nologic or genetic interventions that target tissue factor, endothelial protein C receptor, activated

59 On the contrary, addition of tissue factor enhanced clot contraction, mimicking the e

60 , using human MPM cells that lack or express tissue factor, EPCR or PAR1, and an orthotopic nude mous

61 Tissue factor expressed by eosinophils can induce activa

62 d clot contraction, mimicking the effects of tissue factor expressed on the activated monocytes.

63 ey show how EPCR can attenuate the growth of tissue factor-expressing tumor cells.

64 explained by the ability of Gas6 to promote tissue factor expression and activity.

65 nuclear factor-kappaB-mediated increases in tissue factor expression at both messenger RNA and prote

66 IF1alpha were also associated with increased tissue factor expression in human breast tumor samples.

67 all PDX models, including models that showed tissue factor expression in only 25% to 50% of the tumor

68 cancer cells, and the mechanisms regulating tissue factor expression in these cells remain unclear.

69 nors to lipopolysaccharide increased surface tissue factor expression on all monocyte subsets, but ex

70 Inhibition of tissue factor expression or its inactivation on the surf

71 vity in EC induces an increase in ICAM-1 and tissue factor expression through the upregulation of p38

72 In vitro, thrombin-induced tissue factor expression was reduced in Gas6(-/-) endoth

73 Tissue factor expression was significantly reduced in th

74 ivation (proportions of monocyte subsets and tissue factor expression) and T-cell activation (express

75 nograft (PDX) models with variable levels of tissue factor expression, derived from seven different s

76 Granulocyte tissue factor expression, formation of thrombin-antithro

77 in vitro and in vivo, which was dependent on tissue factor expression.

78 secretion, macrophage-induced apoptosis, and tissue factor expression.

79 script is responsible for the suppression of tissue factor expression.

80 C3 deposition, C5a release, and procoagulant tissue-factor expression.

81 The procoagulant protein tissue factor (F3) is a powerful growth promoter in many

82 I) is an anticoagulant protein that inhibits tissue factor-factor VIIa (TF-fVIIa) and factor Xa (fXa)

83 y Inhibitor (TFPI) is the major inhibitor of tissue factor-factor VIIa (TF-FVIIa)-dependent FXa gener

84 We examined whether the tissue factor/factor VIIa complex initiates the coagulat

85 In fact, inhibition of the tissue factor/factor VIIa complex reduced mortality in a

86 oagulant protein c2, a powerful inhibitor of tissue factor/factor VIIa-dependent coagulation (n = 6),

87 Tissue factor/factor VIIa-dependent pathway initiates co

88 the factor Xa (FXa)-dependent inhibition of tissue factor/factor VIIa.

89 ulation by inhibition of Factor VIIa (FVIIa)/tissue factor/Factor Xa (FVIIa/TF/FXa).

90 lin M, immunoglobulin G, complement, fibrin, tissue factor, fibrinogen-like protein 2, tissue plasmin

91 Full-length tissue factor (flTF), the coagulation initiator, is over

92 endothelial activation/damage, production of tissue factor from monocytes, increased platelet activat

93 entified a chromosome 3 locus containing the tissue factor gene (F3).

94 The tissue factor gene is selectively expressed in highly in

95 The tissue factor gene promoter was activated, and forced ex

96 Tissue factor has been recognized as a regulator of tumo

97 Three tissue factor HuMab, that induced efficient inhibition o

98 n vivo outcomes, such as the upregulation of tissue factor in endothelial cell systems by compounds l

99 Pharmacological blockade of adipocyte tissue factor in vivo reversed these effects of tissue f

100 gressive MPM cells engineered to overexpress tissue factor increased their tumorigenicity.

101 Clotting stimulation by immobilized tissue factor induced localized thrombin activity impuls

102 Tissue factor-induced clotting of plasma led to proteoly

103 dependent feedback inhibition of factor VIIa/tissue factor-induced coagulation.

104 d with recombinant soluble TM showed reduced tissue factor-induced thrombin generation.

105 th separate MR imaging measurements of other tissue factors influencing T2*, it might be possible to

106 suggest that FXIa may provide a link between tissue factor-initiated coagulation and the proteases of

107 and thromboelastography was used to measure tissue factor-initiated fibrin formation and tissue-plas

108 nd elastometry of clots produced in cell and tissue factor-initiated models of thrombosis, we show th

109 h D-Phe-Pro-Arg-CH(2)Cl (FPR-ProT) inhibited tissue factor-initiated thrombin generation in platelet-

110 transfusion, no thrombin was generated in a tissue factor-initiated whole blood clotting assay unles

111 Tissue factor initiates the process of thrombosis and ac

112 Other studies showed that incorporation of tissue factor into the envelope of herpes simplex virus

113 D-dimer and soluble tissue factor levels were significantly elevated in elit

114 in plasma thrombin-antithrombin complex and tissue factor levels.

115 elamer treatment, however, levels of soluble tissue factor, low-density lipoprotein (LDL) cholesterol

116 c factors expressed on tumor cells influence tissue factor-mediated effects on cancer progression.

117 Finally, higher tissue factor messenger RNA levels were measured in the

118 le 1, vascular cell adhesion molecule 1, and tissue factor messenger RNA.

119 ant activity was assessed by a functional MP-tissue factor (MP-TF) assay.

120 tive form, as induced either by its cofactor tissue factor or a covalent active site inhibitor.

121 When they carry tissue factor or coagulation inhibitors, they participat

122 Suppression of tissue factor or PAR1 expression in these cells markedly

123 Inhibition of either tissue factor or thrombin in WT mice also significantly

124 difference among measured levels of D-dimer, tissue factor, or F1+2 between HIV-infected individuals

125 elta12 interfere with polyphosphate- but not tissue factor- or nucleic acid-driven thrombin formation

126 In contrast, tissue factor overexpression in nonaggressive MPM cells

127 in (P = 0.009), and diminished expression of tissue factor (P = 0.005) and fibrinogen-like protein 2

128 In hematopoietic cells, genetic ablation of tissue factor-PAR2 signaling reduced adipose tissue macr

129 C57BL/6 and transgenic mice overexpressing tissue factor pathway inhibitor (SM22alpha-TFPI) were su

130 r F5(L) (F5(L/L) ) and haploinsufficient for tissue factor pathway inhibitor (Tfpi(+/-) ).

131 ompared to HC, as were MPs expressing TF and Tissue Factor Pathway Inhibitor (TFPI) (all p < 0.0001).

132 Tissue factor pathway inhibitor (TFPI) blocks thrombin g

133 Tissue factor pathway inhibitor (TFPI) down-regulates th

134 fibrin formation was associated with reduced tissue factor pathway inhibitor (TFPI) expression and in

135 Tissue factor pathway inhibitor (TFPI) is a critical ant

136 Tissue factor pathway inhibitor (TFPI) is a Kunitz-type

137 Tissue factor pathway inhibitor (TFPI) is an anticoagula

138 Tissue Factor Pathway Inhibitor (TFPI) is the major inhi

139 Tissue factor pathway inhibitor (TFPI) localized at the

140 Tissue factor pathway inhibitor (TFPI) plays an importan

141 Tissue factor pathway inhibitor (TFPI) produces factor X

142 Protein S is a cofactor for tissue factor pathway inhibitor (TFPI) that critically r

143 in vitro thrombin generation, and levels of tissue factor pathway inhibitor (TFPI) were strongly inc

144 Protein S is a cofactor for tissue factor pathway inhibitor (TFPI), accelerating the

145 ein Z-dependent protease inhibitor (ZPI) and tissue factor pathway inhibitor (TFPI), effectively inhi

146 Tissue factor pathway inhibitor (TFPI), the main inhibit

147 emains intact but is negatively regulated by tissue factor pathway inhibitor (TFPI), which inhibits b

148 ated that APC sheds the Kunitz 1 domain from tissue factor pathway inhibitor (TFPI).

149 ld interact with and inhibit the activity of tissue factor pathway inhibitor (TFPI).

150 agulation inhibitors activated protein C and tissue factor pathway inhibitor but also is also a physi

151 allenged with CpG DNA, and tissue factor and tissue factor pathway inhibitor expression and activity

152 lood cells, and an endogenous DPP4 inhibitor tissue factor pathway inhibitor has been discovered, inc

153 e factor, a key initiator of coagulation and tissue factor pathway inhibitor in human coronary artery

154 clot formation, decreasing upon induction of tissue factor pathway inhibitor or treatment with hirudi

155 r 9 shifted the balance of tissue factor and tissue factor pathway inhibitor toward procoagulant phen

156 Conversely, CpG DNA significantly reduced tissue factor pathway inhibitor transcription, secretion

157 in, high activated protein C, protein S, and tissue factor pathway inhibitor) and hyperfibrinolysis (

158 tely abrogates the anticoagulant function of tissue factor pathway inhibitor, enhances fibrin clot st

159 , phospholipid transfer protein, matrilin-3, tissue factor pathway inhibitor, fibrinogen-like 1, and

160 tial thromboplastin times and tissue factor, tissue factor pathway inhibitor, protein C, plasminogen

161 ated FVIII), monoclonal antibodies targeting tissue factor pathway inhibitor, small interfering RNA t

162 n S, soluble endothelial protein C receptor, tissue factor pathway inhibitor, von Willebrand factor,

163 platelet factor V and, surprisingly, plasma tissue factor pathway inhibitor, which is significantly

164 mRNA level of TF but not of its counterpart-tissue factor pathway inhibitor, which was accompanied b

165 th factor activator inhibitor type 2 (HAI2), tissue factor pathway inhibitor-1 (TFPI1), and tissue fa

166 Tissue factor pathway inhibitor-2 (TFPI-2) is a homologu

167 ssue factor pathway inhibitor-1 (TFPI1), and tissue factor pathway inhibitor-2 (TFPI2), as well as E-

168 nhances the inhibition of factor Xa (FXa) by tissue factor pathway inhibitor-alpha (TFPI-alpha) in th

169 indirect mechanism by forming a complex with tissue factor pathway inhibitor-alpha (TFPIalpha), resul

170 d binds tightly to the coagulation regulator tissue factor pathway inhibitor-alpha (TFPIalpha).

171 n hemophilia, possibly through inhibition of tissue factor pathway inhibitor.

172 urally deleted (Kunitz 1-domainless) form of tissue factor pathway inhibitor.

173 possible disruption of FXa inhibition by the tissue factor pathway inhibitor.

174 TFPI2, a Kunitz-type serine protease in the tissue factor pathway that inhibits the initiation of th

175 We identified tissue-factor pathway inhibitor (TFPI) as a biological i

176 creased levels of leukocytes, platelets, and tissue factor-positive (TF(+)) microvesicles (MVs) are a

177 .4% vs 1.2%, P = .002) and in proportions of tissue factor-positive patrolling (CD14(Dim)CD16(+)) mon

178 We found that ATG activated tissue factor procoagulant activity (TF PCA) on monocyti

179 t internalization, but had minimal impact on tissue factor procoagulant activity in vitro, were conju

180 for monocyte matrix metalloproteinase-9 and tissue factor production and promote Ig production in au

181 eatment did not alter cytokine/chemokine and tissue factor production in vitro or affected human isle

182 for monocyte matrix metalloproteinase-9 and tissue factor production, as well as their cytolytic pot

183 mediate proliferation or elicit endothelial tissue factor production, confirming that these function

184 mediated coagulation pathways by diminishing tissue factor production, reducing plasma thrombin-antit

185 Cytokine/chemokine and tissue factor productions were measured in vitro, and is

186 our results enlighten the mechanism by which tissue factor promotes tumor growth through PAR1, and th

187 Tissue factor protein was barely detectable in MCF-7, T4

188 ; a measure of thrombin generation in vivo), tissue factor, prothrombin fragment 1 + 2 (F1+2), and no

189 mucosal dendritic cells and the gut-specific tissue factor retinoic acid (RA).

190 Thus, inhibition of tissue factor signaling is a potential therapeutic avenu

191 fic pharmacological inhibition of macrophage tissue factor signaling rapidly ameliorated insulin resi

192 the aPC-mediated inhibition of inflammatory tissue-factor signaling.

193 Tissue factor-specific ADCs showed potent cytotoxicity i

194 ibody-drug conjugate (ADC), a panel of human tissue factor-specific antibodies (TF HuMab) was generat

195 electin (sE-Selectin), thrombomodulin (sTM), tissue factor (sTF) and vascular endothelial growth fact

196 Tissue factor (TF) (CD142) is a 47 kDa transmembrane cel

197 an blood under thrombotic flow conditions on tissue factor (TF) -bearing surfaces remains inadequatel

198 s had comparable binding to human and murine tissue factor (TF) and exhibited similar extrinsic coagu

199 ecules plasminogen activator inhibitor-1 and tissue factor (TF) and increased platelet activation.

200 I (FVIIa) with zymogen factor VII (FVII) for tissue factor (TF) and loading of the platelet surface w

201 lineate a role for coagulation signaling via tissue factor (TF) and proteinase-activated receptor 2 (

202 rosine kinase and leads to the generation of tissue factor (TF) and thrombin.

203 ent induction of its downstream target genes tissue factor (TF) and vascular cell adhesion molecule-1

204 On the HSV1 surface, host-cell-derived tissue factor (TF) and virus-encoded glycoprotein C (gC)

205 ted whether plasma microparticles expressing Tissue Factor (TF) are increased in BS.

206 Previously, we have shown that inhibition of tissue factor (TF) attenuates activation of coagulation

207 mpetition between FVIIa and FVII zymogen for tissue factor (TF) binding, and (2) a high-dose-requirin

208 Tissue factor (TF) binds the serine protease factor VIIa

209 Constitutive expression of tissue factor (TF) by cancer cells triggers local activa

210 The synthesis of tissue factor (TF) by monocytes/macrophages activated by

211 As microparticles expressing Tissue Factor (TF) can contribute to thrombosis in precl

212 We found that the extrinsic tissue factor (TF) coagulation initiation complex can se

213 prevent contact activation, over a range of tissue factor (TF) concentrations.

214 tor 1 (PAR-1) and hematopoietic cell-derived tissue factor (TF) contribute to hepatic steatosis.

215 They are rescued by concomitant tissue factor (TF) deficiency, demonstrating that TFPI m

216 of the extrinsic pathway of coagulation via tissue factor (TF) derived from myeloid leukocytes cause

217 at pulmonary vascular endothelial VCAM-1 and tissue factor (TF) expression (both are indicators of en

218 tigated the effects of the HIT Ab complex on tissue factor (TF) expression and release of TF-positive

219 Tissue factor (TF) expression by tumor cells correlates

220 In the present study, we analyzed tissue factor (TF) expression in 4 different human pancr

221 In this study, we characterized tissue factor (TF) expression in mouse hepatocytes (HPCs

222 Upregulation of tissue factor (TF) expression leads to increased patient

223 Brain death is also believed to increase tissue factor (TF) expression, contributing to a low rat

224 Some studies suggest that FVIIa requires tissue factor (TF) for function and that the reason for

225 separation of the membrane-anchored cofactor tissue factor (TF) from inactive precursors of coagulati

226 ment leads to a coordinated loss of EGFR and tissue factor (TF) from the plasma membrane and coincide

227 Overexpression of tissue factor (TF) has been associated with increased tu

228 Purpose Circulating tissue factor (TF) has been studied as a biomarker for p

229 duces expression of the procoagulant protein tissue factor (TF) in monocytes.

230 Here, we examined the role of tissue factor (TF) in the activation of coagulation and

231 ecific prothrombotic metabolite that induces tissue factor (TF) in vascular smooth muscle cells (vSMC

232 sin-like serine protease, and membrane-bound tissue factor (TF) initiates blood coagulation upon vasc

233 Tissue factor (TF) is a cell-surface glycoprotein respon

234 Tissue factor (TF) is a critical mediator of direct acut

235 Tissue factor (TF) is a crucial mediator of injury-relat

236 Tissue factor (TF) is a transmembrane receptor and prima

237 Tissue factor (TF) is aberrantly expressed in solid canc

238 Tissue factor (TF) is expressed in vascular and nonvascu

239 Although tissue factor (TF) is its natural receptor, rhFVIIa also

240 Tissue factor (TF) is the cellular receptor for plasma p

241 Tissue factor (TF) is the main initiator of the extrinsi

242 Tissue factor (TF) is upregulated in many solid tumors,

243 n generation were drastically reduced in low tissue factor (TF) mice whereas the absence of factor XI

244 Klkb1(-/-) mice have reduced aortic tissue factor (TF) mRNA, antigen, and activity.

245 uced expression of the coagulation initiator tissue factor (TF) on innate immune cells.

246 Tissue factor (TF) pathway inhibitor (TFPI) is a well-ch

247 udies of the anticoagulant activities of the tissue factor (TF) pathway inhibitor (TFPI) isoforms, TF

248 riant in the human ADTRP [androgen-dependent tissue factor (TF) pathway inhibitor (TFPI) regulating p

249 It includes all reactions of the tissue factor (TF) pathway of coagulation through fibrin

250 The tissue factor (TF) pathway serves both hemostasis and ce

251 usly showed that anti-GRP78 AutoAbs increase tissue factor (TF) procoagulant activity on the surface

252 onocyte matrix metalloproteinase (MMP)-9 and tissue factor (TF) production as well as the CpPLD-induc

253 f this study was to use a well-characterized tissue factor (Tf) reagent and contact pathway inhibitor

254 Here, we aimed to investigate whether tissue factor (TF) was released by endothelial-derived e

255 Thrombosis is initiated by tissue factor (TF), a coagulation cofactor/receptor expr

256 ATP or UTP induces dramatic up-regulation of tissue factor (TF), a key initiator of the coagulation c

257 Here we report that EMT induces tissue factor (TF), a major cell-associated initiator of

258 Tissue factor (TF), a primary initiator of blood coagula

259 Tissue factor (TF), a rate-limiting enzyme cofactor in a

260 ncluding vascular endothelial growth factor, tissue factor (TF), and colony-stimulating factor 1.

261 fects of blood flow, spatial distribution of tissue factor (TF), and the importance of the thrombomod

262 In the absence of its cofactor tissue factor (TF), coagulation factor VIIa (FVIIa) pred

263 r of coagulation, the transmembrane receptor tissue factor (TF), has gained considerable attention as

264 rystal structures of factor (F) VIIa/soluble tissue factor (TF), obtained under high Mg(2+) (50mM Mg(

265 ulation pathway, mediated by factor VIIa and tissue factor (TF), remains intact but is negatively reg

266 de (LPS), whereas mice severely deficient in tissue factor (TF), TF(-/-)hTF(tg), are protected from L

267 vidence that tumor dormancy is influenced by tissue factor (TF), the cancer cell-associated initiator

268 severing bonds between the cytoskeleton and tissue factor (TF), the cell surface receptor responsibl

269 al P2Y receptor(s) mediates up-regulation of tissue factor (TF), the initiator of coagulation cascade

270 The aberrant expression of tissue factor (TF), the primary activator of coagulation

271 n, with consequent increased upregulation of tissue factor (TF), the primary initiator of blood coagu

272 Tissue factor (TF), the primary initiator of coagulation

273 -regulation of proinflammatory cytokines and tissue factor (TF), the principal initiator of the extri

274 f vascular effectors, including procoagulant tissue factor (TF), this study explores whether there is

275 Given that thrombin induces procoagulant tissue factor (TF), we examined how TF activity is affec

276 dylserine (PS), and the procoagulant protein tissue factor (TF), which is the major cellular activato

277 us FVIIa engages its cell-localized cofactor tissue factor (TF), which stimulates activity through me

278 ermediates make to prothrombin activation in tissue factor (Tf)-activated blood, immunoassays were de

279 Here we show in a tissue factor (TF)-dependent model of flow restriction-i

280 es the interaction of FX with human or mouse tissue factor (TF)-FVIIa complexes.

281 del of intravascular platelet deposition and tissue factor (TF)-initiated coagulation under flow is e

282 of prostaglandin (PG) E2, and the amount of tissue factor (TF).

283 Inhibitors of the tissue factor (TF)/factor VIIa complex (TF-FVIIa) are pr

284 patch of type I fibrillar collagen/lipidated tissue factor (TF; approximately 1 TF molecule/mum(2)),

285 xpression of the potent procoagulant protein tissue factor that triggers thrombosis.

286 Tissue factor, the initiator of the coagulation cascade,

287 Our results indicate that the tissue factor/thrombin/PAR-1 pathway enhances IFN-beta e

288 d activated partial thromboplastin times and tissue factor, tissue factor pathway inhibitor, protein

289 MCF-7 cells, implying that the 3'-UTR of the tissue factor transcript is responsible for the suppress

290 9, miR-20, and miR-106b in the 3'-UTR of the tissue factor transcript.

291 using platelet-rich plasma (PRP) showed that tissue factor-triggered thrombin generation was impaired

292 cent MPs promoted EC thrombogenicity through tissue factor upregulation, shedding of procoagulant MPs

293 ane potential, and the induced expression of tissue factor, VEGF, and Flt1.

294 sue factor in vivo reversed these effects of tissue factor-VIIa signaling and rapidly increased energ

295 In contrast, nonhematopoietic cell tissue factor-VIIa-PAR2 signaling specifically promoted

296 evels of thrombin-antithrombin complexes and tissue factor were measured.

297 ng PAR2 (F2rl1) or the cytoplasmic domain of tissue factor were protected from weight gain and insuli

298 platelets and was not ascribable to platelet tissue factor, whereas targeting polyphosphate with phos

299 tor (asTF) is a novel isoform of full-length tissue factor, which exhibits angiogenic activity.

300 in-1, plasminogen activator inhibitor-1, and tissue factor, which positively correlated with fat mass